HUTCHINSON GILFORD PROGERIA TREATMENT MARKET ANALYSIS

Market News

Key Developments

Research and development activities by major institutes to find novel therapies for age-related conditions is expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from the Houston Methodist Research Institute at the Texas Medical Center are focused on using RNA therapeutics—treatment that is focused on ribonucleic acids, a substance found in all living cells—to slow, and possibly reverse Hutchinson-Gilford Progeria.

Similarly, in July 2019, researchers from the University of Oviedo in Spain found that fecal microbiota transplants can help prematurely old mice live longer. The research may help to design targeted probiotic treatments for age-related conditions such as Hutchinson-Gilford Progeria in humans.        

Moreover, in March 2019, researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Universidad de Oviedo identified a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome. The newly identified therapeutic target can be used for blocking early atherosclerosis in progeria.